(NASDAQ: DYN) Dyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.56%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.96%.
Dyne Therapeutics's earnings in 2026 is -$423,801,000.On average, 17 Wall Street analysts forecast DYN's earnings for 2026 to be -$474,320,786, with the lowest DYN earnings forecast at -$604,662,595, and the highest DYN earnings forecast at -$347,920,938. On average, 12 Wall Street analysts forecast DYN's earnings for 2027 to be -$434,486,980, with the lowest DYN earnings forecast at -$670,447,646, and the highest DYN earnings forecast at -$247,443,770.
In 2028, DYN is forecast to generate -$286,777,689 in earnings, with the lowest earnings forecast at -$746,030,470 and the highest earnings forecast at $86,980,234.